The deal is the latest in Moderna’s push to expand beyond COVID as demand for the shots falls dramatically, and develop a vaccine for cancer, a dream that scientists have chased for decades with little success.
Moderna is already developing a cancer vaccine with Merck (MRK.N), which was shown to cut the risk of recurrence or death by 44% in patients with deadly skin cancer melanoma, in a mid-stage trial. It also has vaccines under development for flu and respiratory syncytial virus (RSV), among others.
Under the terms of collaboration, Moderna will lead the development and commercialization of the cancer vaccines resulting from the collaboration, while Immatics will be responsible for pre-clinical and potential early-stage studies.
Immatics will also receive research funding and is eligible for development, regulatory, and commercial milestone payments that could exceed $1.7 billion, Moderna said.